
Tszfung Jackie Chan
Examiner (ID: 9388, Phone: (571)270-7981 , Office: P/2837 )
| Most Active Art Unit | 2837 |
| Art Unit(s) | 2832, 2837 |
| Total Applications | 1062 |
| Issued Applications | 736 |
| Pending Applications | 111 |
| Abandoned Applications | 237 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 19707866
[patent_doc_number] => 20250018008
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-01-16
[patent_title] => USE OF MESENCEPHALIC ASTROCYTE-DERIVED NEUROTROPHIC FACTOR IN PREPARATION OF DRUG FOR TREATING HERPES SIMPLEX KERATITIS
[patent_app_type] => utility
[patent_app_number] => 18/523188
[patent_app_country] => US
[patent_app_date] => 2023-11-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3394
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 29
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18523188
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/523188 | USE OF MESENCEPHALIC ASTROCYTE-DERIVED NEUROTROPHIC FACTOR IN PREPARATION OF DRUG FOR TREATING HERPES SIMPLEX KERATITIS | Nov 28, 2023 | Pending |
Array
(
[id] => 19067205
[patent_doc_number] => 20240101631
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-28
[patent_title] => HUMAN INTERLEUKIN-2 CONJUGATES BIASED FOR THE INTERLEUKIN-2 RECEPTOR BETA-GAMMAC DIMER AND CONJUGATED TO A NONPEPTIDIC, WATER-SOLUBLE POLYMER
[patent_app_type] => utility
[patent_app_number] => 18/484870
[patent_app_country] => US
[patent_app_date] => 2023-10-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 38910
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 53
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18484870
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/484870 | HUMAN INTERLEUKIN-2 CONJUGATES BIASED FOR THE INTERLEUKIN-2 RECEPTOR BETA-GAMMAC DIMER AND CONJUGATED TO A NONPEPTIDIC, WATER-SOLUBLE POLYMER | Oct 10, 2023 | Pending |
Array
(
[id] => 19232196
[patent_doc_number] => 20240189387
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-13
[patent_title] => DOSING REGIMENS FOR HEMATOPOIETIC STEM CELL MOBILIZATION FOR STEM CELL TRANSPLANTS IN MULTIPLE MYELOMA PATIENTS
[patent_app_type] => utility
[patent_app_number] => 18/468506
[patent_app_country] => US
[patent_app_date] => 2023-09-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 49579
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18468506
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/468506 | DOSING REGIMENS FOR HEMATOPOIETIC STEM CELL MOBILIZATION FOR STEM CELL TRANSPLANTS IN MULTIPLE MYELOMA PATIENTS | Sep 14, 2023 | Pending |
Array
(
[id] => 19769967
[patent_doc_number] => 20250051393
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-02-13
[patent_title] => COMPOSITIONS AND METHODS FOR MODULATING INTERFERON REGULATORY FACTOR-5 (IRF-5) ACTIVITY
[patent_app_type] => utility
[patent_app_number] => 18/289943
[patent_app_country] => US
[patent_app_date] => 2022-05-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 73378
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18289943
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/289943 | COMPOSITIONS AND METHODS FOR MODULATING INTERFERON REGULATORY FACTOR-5 (IRF-5) ACTIVITY | May 8, 2022 | Pending |
Array
(
[id] => 19359305
[patent_doc_number] => 20240261339
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-08
[patent_title] => INSECT PROTEIN COMPOSITION FOR THE PREVENTION AND TREATMENT OF CONDITIONS RELATED TO INTESTINAL OXIDATIVE STRESS DAMAGE
[patent_app_type] => utility
[patent_app_number] => 18/563879
[patent_app_country] => US
[patent_app_date] => 2022-05-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19079
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 9
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18563879
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/563879 | INSECT PROTEIN COMPOSITION FOR THE PREVENTION AND TREATMENT OF CONDITIONS RELATED TO INTESTINAL OXIDATIVE STRESS DAMAGE | May 1, 2022 | Pending |
Array
(
[id] => 19248700
[patent_doc_number] => 20240199687
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-20
[patent_title] => SUBSTITUTION OF HISTIDINE WITH 2-THIOHISTIDINE IN BIOACTIVE PEPTIDES
[patent_app_type] => utility
[patent_app_number] => 18/556587
[patent_app_country] => US
[patent_app_date] => 2022-04-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11337
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 51
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18556587
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/556587 | SUBSTITUTION OF HISTIDINE WITH 2-THIOHISTIDINE IN BIOACTIVE PEPTIDES | Apr 21, 2022 | Pending |
Array
(
[id] => 19263709
[patent_doc_number] => 20240207406
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-27
[patent_title] => METHODS AND COMPOSITIONS COMPRISING MHC CLASS I PEPTIDES
[patent_app_type] => utility
[patent_app_number] => 18/556054
[patent_app_country] => US
[patent_app_date] => 2022-04-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 39062
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -226
[patent_words_short_claim] => 22
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18556054
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/556054 | METHODS AND COMPOSITIONS COMPRISING MHC CLASS I PEPTIDES | Apr 17, 2022 | Pending |
Array
(
[id] => 19233748
[patent_doc_number] => 20240190940
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-13
[patent_title] => HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH Q61K MUTATION
[patent_app_type] => utility
[patent_app_number] => 18/286911
[patent_app_country] => US
[patent_app_date] => 2022-04-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19544
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18286911
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/286911 | HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH Q61K MUTATION | Apr 17, 2022 | Pending |
Array
(
[id] => 19281545
[patent_doc_number] => 20240218019
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-07-04
[patent_title] => METHODS AND COMPOSITIONS COMPRISING MHC CLASS I PEPTIDES
[patent_app_type] => utility
[patent_app_number] => 18/554180
[patent_app_country] => US
[patent_app_date] => 2022-04-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 73762
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -163
[patent_words_short_claim] => 18
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18554180
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/554180 | METHODS AND COMPOSITIONS COMPRISING MHC CLASS I PEPTIDES | Apr 5, 2022 | Pending |
Array
(
[id] => 19170944
[patent_doc_number] => 20240156918
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-16
[patent_title] => GEL BASED ON ANNELID HEMOGLOBIN
[patent_app_type] => utility
[patent_app_number] => 18/550192
[patent_app_country] => US
[patent_app_date] => 2022-03-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5491
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 53
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18550192
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/550192 | GEL BASED ON ANNELID HEMOGLOBIN | Mar 13, 2022 | Pending |
Array
(
[id] => 19172471
[patent_doc_number] => 20240158445
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-16
[patent_title] => CYCLIC CELL-PENETRATING PEPTIDES WITH THREE OR MORE HYDROPHOBIC RESIDUES
[patent_app_type] => utility
[patent_app_number] => 18/278259
[patent_app_country] => US
[patent_app_date] => 2022-02-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28764
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18278259
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/278259 | CYCLIC CELL-PENETRATING PEPTIDES WITH THREE OR MORE HYDROPHOBIC RESIDUES | Feb 21, 2022 | Pending |
Array
(
[id] => 16466705
[patent_doc_number] => 20200368242
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-11-26
[patent_title] => USE OF TG02 FOR TREATING GLIOMAS IN PEDIATRIC SUBJECTS
[patent_app_type] => utility
[patent_app_number] => 16/991863
[patent_app_country] => US
[patent_app_date] => 2020-08-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29157
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 34
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16991863
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/991863 | Use of TG02 for treating gliomas in pediatric subjects | Aug 11, 2020 | Issued |
Array
(
[id] => 16282590
[patent_doc_number] => 20200276192
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-09-03
[patent_title] => CANCER TREATMENT METHOD
[patent_app_type] => utility
[patent_app_number] => 16/879664
[patent_app_country] => US
[patent_app_date] => 2020-05-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12790
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 49
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16879664
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/879664 | CANCER TREATMENT METHOD | May 19, 2020 | Abandoned |
Array
(
[id] => 17073722
[patent_doc_number] => 11110101
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-09-07
[patent_title] => Prostate function support formula
[patent_app_type] => utility
[patent_app_number] => 16/867386
[patent_app_country] => US
[patent_app_date] => 2020-05-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 4
[patent_no_of_words] => 3228
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 68
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16867386
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/867386 | Prostate function support formula | May 4, 2020 | Issued |
Array
(
[id] => 16190744
[patent_doc_number] => 20200231593
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-07-23
[patent_title] => SALTS AND CRYSTALLINE FORMS OF AN APOPTOSIS-INDUCING AGENT
[patent_app_type] => utility
[patent_app_number] => 16/843729
[patent_app_country] => US
[patent_app_date] => 2020-04-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15281
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -3
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16843729
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/843729 | SALTS AND CRYSTALLINE FORMS OF AN APOPTOSIS-INDUCING AGENT | Apr 7, 2020 | Abandoned |
Array
(
[id] => 16267220
[patent_doc_number] => 20200268707
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-08-27
[patent_title] => METHODS OF MODULATING PROTEIN EXOCYTOSIS AND USES OF SAME IN THERAPY
[patent_app_type] => utility
[patent_app_number] => 16/833859
[patent_app_country] => US
[patent_app_date] => 2020-03-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30534
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 43
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16833859
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/833859 | METHODS OF MODULATING PROTEIN EXOCYTOSIS AND USES OF SAME IN THERAPY | Mar 29, 2020 | Abandoned |
Array
(
[id] => 16153701
[patent_doc_number] => 20200215083
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-07-09
[patent_title] => Methods for Treating Heart Transplant Rejection
[patent_app_type] => utility
[patent_app_number] => 16/822657
[patent_app_country] => US
[patent_app_date] => 2020-03-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4840
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -4
[patent_words_short_claim] => 25
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16822657
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/822657 | Methods for Treating Heart Transplant Rejection | Mar 17, 2020 | Abandoned |
Array
(
[id] => 17306241
[patent_doc_number] => 11207323
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-12-28
[patent_title] => sGC stimulators
[patent_app_type] => utility
[patent_app_number] => 16/817830
[patent_app_country] => US
[patent_app_date] => 2020-03-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 150932
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 15
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16817830
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/817830 | sGC stimulators | Mar 12, 2020 | Issued |
Array
(
[id] => 16175438
[patent_doc_number] => 20200222406
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-07-16
[patent_title] => METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS
[patent_app_type] => utility
[patent_app_number] => 16/741669
[patent_app_country] => US
[patent_app_date] => 2020-01-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14943
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16741669
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/741669 | METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS | Jan 12, 2020 | Abandoned |
Array
(
[id] => 15866161
[patent_doc_number] => 20200140484
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-05-07
[patent_title] => IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES
[patent_app_type] => utility
[patent_app_number] => 16/737742
[patent_app_country] => US
[patent_app_date] => 2020-01-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14196
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16737742
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/737742 | IBAT inhibitors for the treatment of liver diseases | Jan 7, 2020 | Issued |